



Disclosures

Personal Commercial (3)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott, Amgen, AstraZeneca, Bayer, Chiesi, CSL Behring, DalCor Pharmaceuticals, Daiichi-Sankyo, Edwards, Eli Lilly, Faraday, Janssen, Hikari DX, Novartis, Prolocor, Vertex	Research/Research Grants	Significant (>= \$5,000)	<i>Invasive CV Angio and Interventions</i>
Anthos, Daiichi-Sankyo, Eli Lilly, Haemonetics, Merck,	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Invasive CV Angio and Interventions</i>
AstraZeneca, Bayer, Boehringer Ingelheim, BMS, CSL Behring, Chiesi, Faraday, Idorsia, Janssen, Novartis, Novo Nordisk, SFJ Pharmaceuticals, PLx Pharma, Pfizer, Sanofi, Vectura, Werfen	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Invasive CV Angio and Interventions</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 5/22/2026

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

Confidentiality, Disclosure and Assignment Agreement | Signed on 5/22/2026

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

Embargo | Signed on 5/22/2026

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

On-Going Obligation Agreement | Signed on 5/22/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.